Abstract 743P
Background
Immunotherapy (IO) plus chemotherapy (CT) with maintenance IO has emerged as a new standard first-line treatment for primary advanced or recurrent endometrial cancer (EC) in patients (pts) with deficient DNA mismatch repair (dMMR). For those with mismatch repair–proficient (pMMR) disease, progression-free survival (PFS) magnitude of benefit is smaller, and an overall survival (OS) improvement has not yet been demonstrated. This meta-analysis aims to evaluate the PFS and OS in dMMR and pMMR pts with EC.
Methods
We searched PubMed, Embase, Cochrane and oncology meetings until April 2024. Randomized phase II or III trials (RCTs) investigating IO plus CT in first line for EC were selected. A meta-analysis of extracted individual patient (pt) data (eIPD) was performed. IPD was reconstructed from reported Kaplan-Meier plots through WebPlotDigitizer and the R package IPDfromKM and further combined. A trial-level meta-analysis was also conducted using fixed and random effects models.
Results
Five RCTs were included (NRG-GY018, RUBY, MITO END-3, AtTEnd/ENGOT-en7, DUO-E). 2436 pts were included in PFS analysis: 621 in PFS dMMR (318 in IO arm versus 303 in control arm) and 1815 in PFS pMMR (978 in IO arm and 837 in control arm). In the trial level meta-analysis, both subgroups derived PFS benefit with the addition of IO (dMMR: HR 0.34, 95% CI 0.27-0.44; pMMR: HR 0.77, 95% CI 0.63-0.95). 2317 pts were included in OS analysis: 560 pts in OS dMMR (290 in IO arm and 270 in control arm) and 1757 pts in OS pMMR (947 in IO arm and 810 in control arm). In the trial level meta-analysis, IO improved OS only in the dMMR group (dMMR: HR 0.39, 95% CI 0.27-0.56; pMMR: HR 0.87, 95% CI 0.74-1.02). The results in the eIPD analysis yielded similar results with better outcomes in PFS for all subgroups, with a 3-year absolute gain of 36% in dMMR and 6% in pMMR. An absolute 3-year gain of 28% was observed in OS in the dMMR pts.
Conclusions
IO should be part of the standard of care in first-line for dMMR EC. For pMMR tumors, the clinical relevance of IO was limited, and longer follow-up is warranted. Molecular classification exploratory analysis from these trials can help us to understand who are the pMMR pts that benefit from IO.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M.C. Gouveia: Financial Interests, Personal, Invited Speaker: Novartis. M.R. Mirza: Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, Karyopharm, Merck, Zailab, BioNTech, Daiichi Sankyo, Eisai, ImmunoGen/AbbVie, Incyte, Regeneron; Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK; Financial Interests, Personal, Member of Board of Directors: Karyopharm; Financial Interests, Personal, Stocks/Shares: Karyopharm; Financial Interests, Institutional, Research Grant: GSK, AstraZeneca, Ultimovacs, Apexigen; Financial Interests, Institutional, Trial Chair: Deciphera; Non-Financial Interests, Advisory Role: Ultimovacs; Non-Financial Interests, Member, Member of Prix Galien Awards Committee: Prix Galien Foundation. D. Lorusso: Financial Interests, Personal, Advisory Board, Participation in Advisory Boards and Invited Speaker: GSK, Clovis Oncology, PharmaMar; Financial Interests, Personal, Advisory Board, Participation in Advisory Boards and Invited Speakers: AstraZeneca, MSD; Financial Interests, Personal, Other, Consultancy: PharmaMar, AstraZeneca, Clovis Oncology, GSK, MSD, ImmunoGen, Genmab, Seagen, Novartis; Financial Interests, Personal, Advisory Board, Invited member of advisory board and invited speaker: Seagen, ImmunoGen, Genmab; Financial Interests, Personal, Advisory Board, Invited member of advisory board: Oncoinvest, Corcept, Sutro; Financial Interests, Institutional, Funding, Grant for founding academic trials: MSD, Clovis Oncology, GSK, PharmaMar; Financial Interests, Institutional, Coordinating PI, ENGOT trial with institutional support for coordination: Clovis Oncology; Financial Interests, Institutional, Coordinating PI, ENGOT trial with institutional support for coordination: Genmab, MSD; Financial Interests, Institutional, Funding, Clinical trial/contracted research: AstraZeneca, Clovis Oncology, GSK, MSD, Seagen; Financial Interests, Institutional, Funding, Clinical trials/contracted research: Genmab, ImmunoGen, Incyte, Novartis, Roche; Non-Financial Interests, Principal Investigator, PI of several trials, no compensation received: GSK; Non-Financial Interests, Principal Investigator, PI of several trials. No personal compensation received: AstraZeneca, Genmab; Non-Financial Interests, Principal Investigator, PI in several trials. No personal compensation received: MSD; Non-Financial Interests, Principal Investigator, PI of clinical trial. No personal compensation received: immunogen, Clovis Oncology, Roche, Incyte; Non-Financial Interests, Principal Investigator, PI of several trials, no personal compensation received: Novartis; Non-Financial Interests, Principal Investigator, PI of clinical trial, no personal compensation received: Seagen; Non-Financial Interests, Principal Investigator, PI of clinical trials, no personal compensation received: PharmaMar; Non-Financial Interests, Member, Board of Directors: GCIG; Other Grants for traveling: AstraZeneca, Clovis Oncology, GSK. R. Colombo Bonadio: Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: Adium Pharma, AstraZeneca, Pfizer, Nestle health science, Daiichi Sankyo, BMS, Gilead Sciences; Financial Interests, Institutional, Research Grant: Novartis, AstraZeneca; Other, Travel, Accommodations, Expenses: Daiichi Sankyo, AstraZeneca, MSD. M. Scaranti: Financial Interests, Personal, Advisory Board: MSD, AstraZeneca, Gilead; Financial Interests, Personal, Principal Investigator: AstraZeneca, Libbs, Amgen, Sophia genetics. All other authors have declared no conflicts of interest.
Resources from the same session
651P - Phase I study of XNW27011, a novel claudin 18.2 ADC, in patients with locally advanced and/or metastatic solid tumors
Presenter: Jinming Yu
Session: Poster session 01
652P - BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
Presenter: Oscar Reig Torras
Session: Poster session 01
653P - A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors
Presenter: Matthew Chau Hsien Ng
Session: Poster session 01
654P - Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors
Presenter: Bernard Doger de Spéville
Session: Poster session 01
655P - Toxicity and efficacy of antibody drug conjugates (ADC) in advanced solid tumors: A pooled analysis of Sarah Cannon UK
Presenter: Rachel Woodford
Session: Poster session 01
656P - Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
Presenter: Victor Moreno Garcia
Session: Poster session 01
657P - Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials
Presenter: Noé Herbel
Session: Poster session 01
658P - First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Cátia Fava Gaspar
Session: Poster session 01
659P - Combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer
Presenter: Zev Wainberg
Session: Poster session 01
660P - Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: Safety and efficacy results of the VolATIL phase II study
Presenter: Laura Mansi
Session: Poster session 01